B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Novavax (NASDAQ:NVAX) on Monday, setting a price target of $305, which is approximately 28.40% above the present share price of $237.54.
Mamtani expects Novavax to post earnings per share (EPS) of -$4.75 for the third quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Novavax, with an average price target of $290.33.
The analysts price targets range from a high of $305 to a low of $272.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $298.02 million and a net profit of -$345.83 million. The company's market cap is $17.69 billion.
According to TipRanks.com, B.Riley Financial analyst Mayank Mamtani is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 18.3% and a 48.40% success rate.
Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.